"Another round of explanations and new strategies in the clinic...

"Another round of explanations and new strategies in the clinic [from Amgen] isn’t likely going to be well received by anyone. But don’t expect anyone to lose interest now. Mastering KRAS has game-changing potential in oncology — for whoever comes out on top."

Thanks for keeping us uptodate with what's with KRAS trials, Dalts. Interesting that Lumakras achieves positive outcomes as a monotherapy but disappointed in combo with the PD1 checkpoint inhibitor. The concern is that perhaps KRAS targeted therapies may not be as successful as had hoped in combo with immunotherapy drugs. Attention will now turn to Mirati with their more promising combo results to date - in the hope that Amgen's results aren't indicative of a class response.

Certainly an interesting space. It was brought up in the recent panel discussion with Dan Shelly who presented for PTX, that the FDA is focusing in on targeted therapies. The outcomes to our PTX100 expansion trial is going to have much attention on it. Its safety as a monotherapy has already been established to a large degree... so, now its all about the efficacy data (and, to a lesser degree, any other interesting indications it may throw up as a target against KRAS).a

Can't not sign off without mentioning the sad loss of Olivia Newton-John. Such a wonderful lady who battled cancer for decades, did so much to help others and touched people across the world with her generosity, determination and down-to-earth nature. Her legacy will live on with the Olivia Newton-John Cancer Research and Wellness Institute in Melbourne. Sad day.